NICE is unable to recommend panitumumab with 5‑fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults because no evidence submission was received from the manufacturer or sponsor of the technology.

We have published guidance on cetuximab and panitumumab for previously untreated metastatic colorectal cancer.

Since the publication of TA240, the population covered by the marketing authorisation for panitumumab has changed from ‘patients with wild-type KRAS metastatic colorectal cancer’ to ‘patients with wild-type RAS metastatic colorectal cancer’.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)